Jasper Therapeutics to Participate at Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company […]
Natural Alternatives International, Inc. Announces 2025 Q1 Results
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and […]
Springbig Announces Third Quarter 2024 Financial Results and Amendment to its $6.4 million Convertible Notes and $1.6 million Term Loan
Company achieves positive Adjusted EBITDA* for the third consecutive quarter, reaching $0.9 million year-to-date, a $4.3 million improvement year-on-year Third-quarter […]
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
– Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology – […]
3D Systems Announces Preliminary Third Quarter 2024 Revenue Results
Preliminary third quarter 2024 revenue to be approximately $113 million* Q3 materials grew 10% year-over-year and 9% sequentially, offset by […]
BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024
MISSISSAUGA, Ontario, Nov. 13, 2024 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its […]
Telix ADSs Commence Trading on Nasdaq
MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that […]
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human […]
